Category: 1317-39-1

Catalysts function by providing an alternate reaction mechanism that has a lower activation energy than would be found in the absence of the catalyst. In some cases, the catalyzed mechanism may include additional steps.In a article, 1317-39-1, molcular formula is Cu2O, introducing its new discovery. 1317-39-1

Method of use of, and compositions containing, disubstituted xanthone carboxylic acid compounds

Compositions containing and methods employing, as the essential ingredient, novel disubstituted xanthone carboxylic acid compounds which are useful in the treatment of allergic conditions. Methods for preparing these compounds and compositions and intermediates therein are also disclosed. 5-Methylthio-7-isopropoxyxanthone-2-carboxylic acid and 5,7-di-(methylthio)xanthone-2-carboxylic acid are illustrated as representative compounds.

Because enzymes can increase reaction rates by enormous factors and tend to be very specific, 1317-39-1, typically producing only a single product in quantitative yield, they are the focus of active research.you can also check out more blogs about 1317-39-1

Reference£º
Copper catalysis in organic synthesis – NCBI,
Special Issue “Fundamentals and Applications of Copper-Based Catalysts”

 

1317-39-1, Catalysts function by providing an alternate reaction mechanism that has a lower activation energy than would be found in the absence of the catalyst. In a patent, 1317-39-1, molecular formula is Cu2O, introducing its new discovery.

Pyridine derived agents for cardiovascular diseases

STR1 Compounds of formula (I) or a biolabile ester thereof, or a pharmaceutically acceptable salt of either, wherein Rl, R2, R3 and R4 are each independently selected from H or C1 -C4 alkyl; R5 is (CH2)m SO2 R6, (CH2)m NHSO2 R6 or (CH2)m NHCOR7 ; R6 and R7 are C1 -C6 alkyl, C1 -C3 perfluoroalkyl(CH2)n, C3 -C6 cycloalkyl(CH2)n, aryl(CH2)n or heteroaryl(CH2)n ; or R6 is NR8 R9 ; R8 is H or C1 -C4 alkyl; R9 is C1 -C6 alkyl, C3 -C6 cycloalkyl(CH2)n, aryl(CH2)n or heteroaryl(CH2)n ; or R8 and R9 together with the nitrogen atom to which they are attached form a 5- to 7-membered heterocyclic ring which may optionally incorporate a carbon-carbon double bond or a further hetero atom linkage selected from O, S, NH, N(C1 -C4 alkyl) and N(C1 -C5 alkanoyl), and which may optionally be substituted with one to three substituents each independently selected from C1 -C4 alkyl and C1 -C4 alkoxy, and which may optionally be benzo-fused; X is CH2, CHCH3, C(OH)CH3, C=CH2 or O; m is 0 or 1; n is 0, 1, 2 or 3; and Het is 3- or 4-pyridyl or 1-imidazolyl; with the proviso that when Het is 1-imidazolyl then X is CH2 or CHCH3, are combined thromboxane A2 synthetase inhibitors and thromboxane A2 /endoperoxide antagonists of utility in the treatment of disease conditions in which thromboxane A2 is a causative agent.

Note that a catalyst decreases the activation energy for both the forward and the reverse reactions and hence accelerates both the forward and the reverse reactions.1317-39-1, you can also check out more blogs about1317-39-1

Reference£º
Copper catalysis in organic synthesis – NCBI,
Special Issue “Fundamentals and Applications of Copper-Based Catalysts”

 

1317-39-1, Catalysts function by providing an alternate reaction mechanism that has a lower activation energy than would be found in the absence of the catalyst. In a patent, 1317-39-1, molecular formula is Cu2O, introducing its new discovery.

Use of completely linear short chain alpha-glucans as a pharmaceutical excipient

This patent pertains to a tablet comprising as a binder a low amylose starch, which has been fully debranched using isoamylase and the method of making such tablet. Such binders are useful in any tabletting method, including direct compression, and can be used as a replacement for microcrystalline cellulose.

Note that a catalyst decreases the activation energy for both the forward and the reverse reactions and hence accelerates both the forward and the reverse reactions.1317-39-1, you can also check out more blogs about1317-39-1

Reference£º
Copper catalysis in organic synthesis – NCBI,
Special Issue “Fundamentals and Applications of Copper-Based Catalysts”

 

Chemistry is the experimental and theoretical study of materials on their properties at both the macroscopic and microscopic levels.In a patent£¬Which mentioned a new discovery about 1317-39-1, molcular formula is Cu2O, introducing its new discovery. , 1317-39-1

Certain substituted imidazo [1,2-a] pyridines

Certain novel substituted imidazo [1,2-a] pyridines with a substituted amino group at the 2- or 3-position are active anthelmintic agents. The novel compounds are prepared from the appropriate substituted 2-aminopyridine precursor. Compositions which utilize said novel imidazo [1,2-a] pyridines as the active ingredient thereof for the treatment of helminthiasis are also disclosed.

Because enzymes can increase reaction rates by enormous factors and tend to be very specific, 1317-39-1, typically producing only a single product in quantitative yield, they are the focus of active research.you can also check out more blogs about 1317-39-1

Reference£º
Copper catalysis in organic synthesis – NCBI,
Special Issue “Fundamentals and Applications of Copper-Based Catalysts”

 

Catalysts function by providing an alternate reaction mechanism that has a lower activation energy than would be found in the absence of the catalyst. In some cases, the catalyzed mechanism may include additional steps.In a article, 1317-39-1, molcular formula is Cu2O, introducing its new discovery. 1317-39-1

Method of use of, and compositions containing, disubstituted xanthone carboxylic acid compounds

Compositions containing and methods employing, as the essential ingredient, novel disubstituted xanthone carboxylic acid compounds which are useful in the treatment of allergic conditions. Methods for preparing these compounds and compositions and intermediates therein are also disclosed. 5-Methylthio-7-isopropoxyxanthone-2-carboxylic acid and 5,7-di-(methylthio)xanthone-2-carboxylic acid are illustrated as representative compounds.

Because enzymes can increase reaction rates by enormous factors and tend to be very specific, 1317-39-1, typically producing only a single product in quantitative yield, they are the focus of active research.you can also check out more blogs about 1317-39-1

Reference£º
Copper catalysis in organic synthesis – NCBI,
Special Issue “Fundamentals and Applications of Copper-Based Catalysts”

 

1317-39-1, Catalysts function by providing an alternate reaction mechanism that has a lower activation energy than would be found in the absence of the catalyst. In a patent, 1317-39-1, molecular formula is Cu2O, introducing its new discovery.

Pyridine derived agents for cardiovascular diseases

STR1 Compounds of formula (I) or a biolabile ester thereof, or a pharmaceutically acceptable salt of either, wherein Rl, R2, R3 and R4 are each independently selected from H or C1 -C4 alkyl; R5 is (CH2)m SO2 R6, (CH2)m NHSO2 R6 or (CH2)m NHCOR7 ; R6 and R7 are C1 -C6 alkyl, C1 -C3 perfluoroalkyl(CH2)n, C3 -C6 cycloalkyl(CH2)n, aryl(CH2)n or heteroaryl(CH2)n ; or R6 is NR8 R9 ; R8 is H or C1 -C4 alkyl; R9 is C1 -C6 alkyl, C3 -C6 cycloalkyl(CH2)n, aryl(CH2)n or heteroaryl(CH2)n ; or R8 and R9 together with the nitrogen atom to which they are attached form a 5- to 7-membered heterocyclic ring which may optionally incorporate a carbon-carbon double bond or a further hetero atom linkage selected from O, S, NH, N(C1 -C4 alkyl) and N(C1 -C5 alkanoyl), and which may optionally be substituted with one to three substituents each independently selected from C1 -C4 alkyl and C1 -C4 alkoxy, and which may optionally be benzo-fused; X is CH2, CHCH3, C(OH)CH3, C=CH2 or O; m is 0 or 1; n is 0, 1, 2 or 3; and Het is 3- or 4-pyridyl or 1-imidazolyl; with the proviso that when Het is 1-imidazolyl then X is CH2 or CHCH3, are combined thromboxane A2 synthetase inhibitors and thromboxane A2 /endoperoxide antagonists of utility in the treatment of disease conditions in which thromboxane A2 is a causative agent.

Note that a catalyst decreases the activation energy for both the forward and the reverse reactions and hence accelerates both the forward and the reverse reactions.1317-39-1, you can also check out more blogs about1317-39-1

Reference£º
Copper catalysis in organic synthesis – NCBI,
Special Issue “Fundamentals and Applications of Copper-Based Catalysts”

 

Chemistry is the experimental and theoretical study of materials on their properties at both the macroscopic and microscopic levels.In a patent£¬Which mentioned a new discovery about 1317-39-1, molcular formula is Cu2O, introducing its new discovery. , 1317-39-1

Preparation of dibenzo[b,f]thiepin compounds

The preparation of dibenzo[b,f]thiepin compounds by a process comprising the direct carboxylation of an ortho-toluyl-aryl sulfide to introduce a phenylacetic acid side chain is disclosed.

Because enzymes can increase reaction rates by enormous factors and tend to be very specific, 1317-39-1, typically producing only a single product in quantitative yield, they are the focus of active research.you can also check out more blogs about 1317-39-1

Reference£º
Copper catalysis in organic synthesis – NCBI,
Special Issue “Fundamentals and Applications of Copper-Based Catalysts”

 

1317-39-1, Chemistry is the experimental and theoretical study of materials on their properties at both the macroscopic and microscopic levels.In a patent£¬Which mentioned a new discovery about 1317-39-1

Aromatic amino-alcohol derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses

Compounds of formula (I): STR1 (wherein: R0 is hydrogen, methyl or hydroxymethyl; R1 is substituted alkyl; R2 and R3 are each hydrogen, halogen, hydroxy, alkoxy, carboxy, alkoxycarbonyl, alkyl, nitro, haloalkyl, or substituted alkyl; X is oxygen or sulfur; and Ar optionally substituted phenyl or naphthyl); and pharmaceutically acceptable salts thereof have a variety of valuable pharmaceutical activities, including anti-diabetic and anti-obesity activities; in addition, they are capable of treating or preventing hyperlipemia and hyperglycemia and, by inhibiting the action of aldose reductase, they can also be effective in the treatment and prevention of complications of diabetes.

1317-39-1, If you are hungry for even more, make sure to check my other article about 1317-39-1

Reference£º
Copper catalysis in organic synthesis – NCBI,
Special Issue “Fundamentals and Applications of Copper-Based Catalysts”

 

In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 1317-39-1, name is Copper(I) oxide, introducing its new discovery. 1317-39-1

Tetralin esters of phenols or benzoic acids having retinoid like activity

Retinoid-like activity is exhibited by compounds of the formula STR1 where the R groups are independently hydrogen, or lower alkyl; A is –C(O)O–, –OC(O)–, –C(O)S–, or –SC(O)–; n is 0-5; and Z is H, –COB where B is –OH or a pharmaceutically acceptable salt, or B is –OR 1 where R 1 is an ester-forming group, or B is –N(R) 2 where R is hydrogen or lower alkyl, or Z is –OE where E is hydrogen or an ether-forming group or –COR 2 where R 2 is hydrogen, lower alkyl, phenyl or lower alkyl phenyl, or Z is –CHO or an acetal derivative thereof, or Z is –COR 3 where R 3 is –(CH 2) m CH 3 where m is 0-4 and the sum of n and m does not exceed 4.

Note that a catalyst decreases the activation energy for both the forward and the reverse reactions and hence accelerates both the forward and the reverse reactions.1317-39-1, you can also check out more blogs about1317-39-1

Reference£º
Copper catalysis in organic synthesis – NCBI,
Special Issue “Fundamentals and Applications of Copper-Based Catalysts”

 

1317-39-1, Catalysts function by providing an alternate reaction mechanism that has a lower activation energy than would be found in the absence of the catalyst. In a patent, 1317-39-1, molecular formula is Cu2O, introducing its new discovery.

N,N-DI-ALKYL(PHENOXY)BENZAMIDE DERIVATIVES

The present invention relates to compounds of the formula: STR1 and the pharmaceutically acceptable salts thereof, wherein Z can be: STR2 wherein R 3 is alkyl having 1 to 6 carbon atoms and, when n is greater than 1, each R 3 can be the same or different; and n is an integer from 1 to 3;

R 1 and R 2 can each independently be hydrogen, straight or branched chain alkyl, or cycloalkyl having 3 to 8 carbon atoms which can optionally be substituted at one or more positions by alkyl of 1 to 6 carbon atoms; X is oxygen, sulfur, NR 4, wherein R 4 is hydrogen or alkyl having 1 to 4 carbon atoms, C=O, CHOH, or CH 2 ; Y is hydrogen, alkoxy, halogen, alkyl, or hydroxy; and m is an integer from 0 to 3. The compounds are antagonists of platlet-activating factor (PAF).

Note that a catalyst decreases the activation energy for both the forward and the reverse reactions and hence accelerates both the forward and the reverse reactions.1317-39-1, you can also check out more blogs about1317-39-1

Reference£º
Copper catalysis in organic synthesis – NCBI,
Special Issue “Fundamentals and Applications of Copper-Based Catalysts”